Which non-steroidal anti-inflammatory drug (NSAID) is safer in patients with Non-steroids Exacerbated Respiratory Disease (N-ERD)? A single-center retrospective study
Tuberk Toraks · 12.12.2022 · 70 (4) · 365-374
DOI: 10.5578/tt.20229608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberk Toraks, online erschienen am 12.12.2022. Verfasst von Mehmet Erdem Çakmak. Beteiligte Einrichtung: Clinic of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Respiratory Tract Diseases, Respiratory Hypersensitivity. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinic of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye.
Zitieren
APA
Çakmak, M. E. (2022). Which non-steroidal anti-inflammatory drug (NSAID) is safer in patients with Non-steroids Exacerbated Respiratory Disease (N-ERD)? A single-center retrospective study. Tuberk Toraks, 70(4), 365-374. https://doi.org/10.5578/tt.20229608
Vancouver
Çakmak ME. Which non-steroidal anti-inflammatory drug (NSAID) is safer in patients with Non-steroids Exacerbated Respiratory Disease (N-ERD)? A single-center retrospective study. Tuberk Toraks. 2022;70(4):365-374. doi:10.5578/tt.20229608
BibTeX
@article{akmak2022,
author = {Çakmak, Mehmet Erdem},
title = {Which non-steroidal anti-inflammatory drug (NSAID) is safer in patients with Non-steroids Exacerbated Respiratory Disease (N-ERD)? A single-center retrospective study},
journal = {Tuberk Toraks},
year = {2022},
volume = {70},
number = {4},
pages = {365--374},
doi = {10.5578/tt.20229608}
}
EUVIMED